Improving sleep isn’t enough: researchers highlight daytime function as key to assessing insomnia treatments
image:
N/A
view moreCredit: University of Maryland School of Medicine
About one in nine adults suffer from chronic insomnia and its residual effects like drowsiness, cognitive issues, and irritability as well as increased health risks like diabetes and heart risks if left untreated. While many treatments are available, the challenge lies in determining how well a medication or other sleep aid works in individual patients.
Now a new study from the University of Maryland School of Medicine has found using real-time smartphone-based assessments can help to determine the effectiveness of sleep medications by detecting improvements in daytime insomnia symptoms including thinking, fatigue, and mood. Following a two-week course of treatment, this smartphone-based assessment approach detected treatment effects more powerfully than did traditional methods like recall questionnaires.
Results were published in JAMA Network Open.
The clinical trial involved 40 older adults ages 60 to 85 with chronic insomnia who were randomly assigned to take the sleep medication suvorexant or a placebo for 16 nights. Both groups used a smartphone app to record their daytime insomnia symptoms in real-time, four times per day throughout the study. Participants also completed traditional questionnaires assessing their sleep patterns and daytime symptoms both before and after treatment.
Key Findings
- Traditional questionnaires detected an overall improvement in insomnia severity between the treatment and placebo groups, but detected no significant differences in daytime symptoms.
- The smartphone-based assessment approach, called ecological momentary assessment (EMA), revealed subtle and important differences between the two groups: Compared to a placebo, suvorexant increased fatigue in the morning, but reduced fatigue in the afternoon and evening. Likewise, alert cognition was lower early in the day in the suvorexant group but normalized as the day progressed.
- Participants who took suvorexant reported numerically worse moods at all 4 times of day compared to those who took a placebo, although differences were not statistically significant.
- Participants found the smartphone assessment was easy to use, with a completion rate of 93.3% across all surveys, demonstrating feasibility and strong engagement.
“Daytime symptoms such as fatigue, cognitive impairment, and mood disturbances are core features of insomnia,” said study corresponding author Emerson M. Wickwire, PhD, faculty member at the University of Maryland School of Medicine and section chief of sleep medicine at the University of Maryland Medical Center. “Improving sleep is not enough. We need to determine how well treatments improve daytime functioning, which patients report matters most. In this study we found that retrospective questionnaires failed to detect subtle treatment-related changes that were detected via the smartphone assessment.”
Implications for Patients and Doctors
This is the first randomized controlled trial to incorporate a smartphone EMA as an outcome measure in a sleep-focused clinical trial. It was able to detect clear treatment effects at various times of the day and was found to be easy to use and sustainable. Leveraging wearables and smartphones for real-time, multimethod assessment should be considered in future studies that evaluate treatment for insomnia as well as other sleep disorders including obstructive sleep apnea and excessive sleepiness that leads to prolonged sleep.
“These findings address a critical gap in sleep disorders clinical care and research,” said Dr. Wickwire. “When viewed as a complement to traditional approaches, EMA offers a sensitive and patient-centered way to measure treatment effects throughout the day, in real-time. Such approaches could transform how we evaluate sleep treatments, personalize sleep medicine care, and ultimately improve outcomes for the millions of Americans with sleep disorders.”
Shuo Chen, PhD, Professor of Epidemiology & Public Health at UMSOM, Avelino Verceles, MD, MS, Professor of Medicine at UMSOM, and University of Maryland graduate student Jingsong Zhou, MS were co-authors on this study. Funding for this study was supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc.
“This research underscores the potential for innovative digital tools to be used in conducting comparative effectiveness studies,” said UMSOM Dean Mark T. Gladwin, MD, who is the Vice President for Medical Affairs, University of Maryland, Baltimore (UMB), and the John Z. and Akiko K. Bowers Distinguished Professor and Dean at UMSOM. "Smartphone-based assessments can provide real-time insights that help improve patient outcomes across a range of common conditions.”
Journal
JAMA Network Open
Method of Research
Randomized controlled/clinical trial
Subject of Research
People
Article Title
Smartphone-Based Real-Time Assessment of Daytime Insomnia Symptoms With Suvorexant A Randomized Clinical Trial
Article Publication Date
5-Jan-2026
COI Statement
Dr Wickwire reported receiving personal fees from DayZz, Eisai, EnsoData, Isorsia, Merck, Nox Health, Primasun, Purdue, and ResMed and grants from ResMed outside the submitted work; and being the inventor of and a shareholder in WellTap. Dr Steenbergh reported being a cofounder and equity holder of LifeData LLC. Dr Buysse reported receiving personal fees from use of the Daytime Insomnia Symptoms Scale outside the submitted work. No other disclosures were reported.
